Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$273.14 USD

273.14
4,131,023

+0.10 (0.04%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $273.09 -0.05 (-0.02%) 7:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (103 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Aparajita Dutta headshot

Pharma's $370B Bet on America: The ETF Plays for 2026

by Aparajita Dutta

Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Zacks Equity Research

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant

by Zacks Equity Research

JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.

Kinjel Shah headshot

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

by Kinjel Shah

J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

Zacks Equity Research

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Sundeep Ganoria headshot

How AbbVie's Pipeline Is Lining Up Key Product Launches

by Sundeep Ganoria

ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.

Zacks Equity Research

FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer

by Zacks Equity Research

JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.

Zacks Equity Research

MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH

by Zacks Equity Research

Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.

Zacks Equity Research

Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus

by Santanu Roy

Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.